New research suggests that people who discontinue popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise plans.
Research printed in a leading medical journal points out that while overweight individuals frequently drop substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"People using these drugs should be informed of the potential of rapid weight regain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
That rate of regain means a reversion to pre-treatment weight within about 18 months.
Weighing Approaches
The research, which reviewed dozens of studies involving thousands of participants, contrasted the results of GLP-1 agonists with older methods.
Researchers note that people who lose weight through lifestyle changes alone usually see a more gradual creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Rapid Regain
Doctors believe the way of the injections accounts for the amplified rebound.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of the hormone concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and could diminish sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication means hunger is no longer kept in check, making overeating far more likely."
A Chronic Issue?
The NHS suggest the injections for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
Professionals say that, due to the significant potential of relapse, the treatment should be considered life-long.
This opinion is supported by drug manufacturers, who state that the findings "emphasize the persistent nature of excess weight," similar to managing conditions like hypertension.
User Accounts
People who have stopped the jabs explain a intense resurgence of hunger.
"I experienced a switch that goes on and you become ravenous," said one woman.
The struggle is compounded if users have not established permanent dietary or behavioural modifications during treatment.
Significant Use
Survey data suggest that a significant number of adults in the UK have used these injections in the last 12 months, with desire being substantial.
- Adoption is more common among females compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Ultimately, clinicians stress that while the jabs are potent tools for weight loss, they are not a magic cure and maintained weight loss likely depends on ongoing behavioural support.
